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Abstract: Next-generation sequencing (NGS) yields powerful opportunities for studying human 
papillomavirus (HPV) genomics for applications in epidemiology, public health, and clinical diag-
nostics. HPV genotypes, variants, and point mutations can be investigated in clinical materials and 
described in previously unprecedented detail. However, both the NGS laboratory analysis and bio-
informatical approach require numerous steps and checks to ensure robust interpretation of results. 
Here, we provide a step-by-step review of recommendations for validation and quality assurance 
procedures of each step in the typical NGS workflow, with a focus on whole-genome sequencing 
approaches. The use of directed pilots and protocols to ensure optimization of sequencing data 
yield, followed by curated bioinformatical procedures, is particularly emphasized. Finally, the stor-
age and sharing of data sets are discussed. The development of international standards for quality 
assurance should be a goal for the HPV NGS community, similar to what has been developed for 
other areas of sequencing efforts including microbiology and molecular pathology. We thus propose 
that it is time for NGS to be included in the global efforts on quality assurance and improvement of 
HPV-based testing and diagnostics. 
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1. Introduction 
Tests for the detection of human papillomavirus (HPV) infection in humans have 
evolved dramatically over the last decades. Initial low-throughput hybridization/blotting 
techniques prefaced broad-spectrum signal amplification assays, which were then re-
placed by rapid high-throughput target-amplification assays involving quantitative poly-
merase chain reaction (qPCR). The latter tests are capable of detecting individual HPV-
genotypes and have become the mainstay of HPV-based screening and clinical testing [1]. 
Arguably, the next “age” of HPV testing should involve going beyond simply detecting 
the presence or absence of HPV but, rather, providing more detailed insight into the likely 
course and clinical consequences of HPV infection. 
Next-generation sequencing (NGS) of human or microbial genetic material is being 
applied increasingly in laboratory contexts, to facilitate research, population-based epide-
miology, and recently, personalized patient diagnostics. NGS can be used as a highly 
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sensitive method for HPV detection due to its ability to detect types at low copy number 
(even within multiple infections), novel types, and/or known types that are distantly re-
lated to primers/probes which may escape detection using standard molecular ap-
proaches [2–4]. When employing whole-genome NGS, which covers the entire genome 
and not only exomes or targeted regions, we conveniently allow high-accuracy determi-
nation of sequences below the phylogenetic level of genotype, i.e., variants and subvari-
ants of HPV [3–8]. Indeed, in recent years, various studies have utilized NGS approaches 
to generate detailed insights into potential disease-related mechanisms of HPV. NGS has 
shown that certain sublineages of HPV are associated with a higher risk of cancer [9–11], 
and its high sensitivity also allows the attributable fraction of cervical cancer associated 
with HPV to be determined with greater precision compared to traditional PCR tech-
niques [12,13]. Further, NGS has identified certain single-nucleotide polymorphisms 
(SNPs) associated with a higher likelihood of viral persistence [14] and the key role of 
HPV E7 gene conservation in cervical cancer development [15]. 
Although NGS has been used in HPV research for some years with different applica-
tions, as described above, NGS in clinical diagnosis is not yet extensively used. Lack of 
standardization and quality guidelines, as well as expense and requirement for ancillary 
laboratory infrastructure, may have slowed down the adoption of this technology in clin-
ical laboratories. However, as is discussed later, NGS use could ultimately improve diag-
nosis and management of patients with HPV-driven lesions. This includes utilities rang-
ing from a more sensitive detection of HPV to detection of true viral persistence [13], iden-
tification of risk according to HPV sublineage [9–11], and detection of circulating HPV 
DNA in patients who have received cancer treatment [16]. 
NGS is a technology based on massively parallel sequencing or “deep sequencing” 
of nucleic acid sequences. Nucleic acid sequences are fragmented with each fragment be-
ing amplified and sequenced multiple times, providing a depth of information which can 
deliver accurate data at the nucleotide level. NGS can sequence the entire genome of HPV 
or be limited to specific areas of interest [11,14]. 
There are several general approaches to sequencing, depending on the size (i.e., 
length) of nucleotide reads obtained and detection method employed. Illumina and Ion-
Torrent instruments obtain reads that are approximately 250 base pair (bp) long, whereas 
Oxford Nanopore MinIon and PacBio obtain longer reads, potentially exceeding 10,000 
bp in length [17]. 
The whole NGS process requires several steps, which include initial sample identifi-
cation, processing (nucleic acid extraction), viral enrichment (optional), library prepara-
tion, sequencing, and bioinformatic analysis of the raw data (Figure 1). While some of 
these steps are consistent with general requirements for molecular detection (i.e., sample 
extraction), the described downstream aspects arguably require an additional set of skills 
and analyses. Given the multistep nature of the process and the generation of large 
amounts of detailed data generated, it is essential that, where possible, standardization 
and quality checks to support consistency and integrity of data outputs are considered 
and implemented. For other applications, including those relevant to bacteriology and 
molecular pathology, quality guidelines have already been developed [18–20]. However, 
these are still lacking for the HPV field. Our chief aim is to provide a comprehensive start-
ing point to widen perspectives and give practical advice for those who are new(er) to this 
topic, thus lowering barriers to introduce NGS specifically in HPV-based research and 
clinical applications. 




Figure 1. Next-generation sequencing (NGS) for human papillomavirus (HPV) detection and characterization process 
steps, from sample preparation to data analysis, with focus on whole-genome sequencing (WGS). 
We are active in the field of HPV testing at the International HPV Reference Labora-
tory and the Scottish HPV Reference Laboratory (SHPVRL). Both entities were established 
in 2008, under the auspices of WHO (LabNet) and through the National Health Service of 
Scotland respectively. As such, we are committed to the evaluation and application of new 
technologies, including NGS technology, specifically to support the prevention and man-
agement of human cancers associated with HPV. In the present work we discuss the key 
stages of HPV-specific applications utilizing NGS and offer practical suggestions for qual-
ity-assurance procedures to support these stages, focusing on HPV whole-genome se-
quencing approaches. We believe that our experience may facilitate the implementation 
of NGS in laboratory settings so that it can play an increasing role in research, epidemiol-
ogy, and importantly clinical testing. With respect to the latter, this is an important con-
sideration, given the increased incorporation of NGS systems into routine departments of 
laboratory medicine, partly because of national strategies designed to harness the benefits 
of genomic medicine at the patient level in an agile but comprehensive way [21]. NGS is 
also consistent with the concept and aspirations of precision medicine, defined as an “ap-
proach for disease treatment and prevention that takes into account variability in genes, 
environment and lifestyle for each patient” [22]. 
2. Materials and Methods 
2.1. NGS-Process Step 1: Laboratory Procedures 
2.1.1. Pre-Analytical Sample Processing 
All specimens used for the identification of HPV by existing molecular tests can in 
theory be used for NGS. However, various biospecimen types may present their own 
unique challenges. Liquid-based cytology samples, swab samples, or fresh frozen biopsies 
may typically be readily applied on an NGS platform. However, cells and tissue derived 
from formalin-fixed paraffin embedded (FFPE) material are more likely to be associated 
with fragmented nucleic acid and crosslinks between intracellular macromolecules such 
as proteins and DNA. Fragmentation can be a rate-limiting factor in approaches that 
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demand longer amplicons, which is why it is useful to note that researchers have success-
fully used shorter amplicons when working with FFPE DNA using NGS technologies [23–
26]. 
2.1.2. Nucleic Acid Extraction Method 
Ideally, extraction methods should be assessed with a pilot panel of samples before 
embarking on a large project, in order to determine the quality and suitability of the spe-
cific extract for downstream NGS. Where possible, we recommend investigators evaluate 
at least two different extraction technologies to maximize nucleic acid yield. The quality, 
quantity, and fragment length prior to the library preparation must be determined, as dif-
ferent library preparations may require different nucleic acid input, quality, and length 
recommendations for library success. For Illumina (San Diego, CA, USA) DNA libraries 
for example, most of the protocols are optimized for 1 ng of input. Assessing the DNA 
purity is needed to ensure that the extract does not contain possible contaminants (EDTA, 
phenol, and ethanol) which can result in assay failure. UV absorbance is a common 
method used for assessing the purity of a DNA sample, and protocols generally define 
the “pure”/acceptable range as having an absorbance ratio values of 1.8–2.0 [27,28]. 
Highly fragmented nucleic acid extraction can lead to missing regions and sections with 
a low number of reads (low coverage), and the analysis may fail if subjected to enrich-
ment-based amplification methods (see further below) [29,30]. Fragment length can be 
analyzed using a qPCR with specific length amplicons (same as target amplicon size if 
PCR-based enrichment is used) or through gel electrophoresis. As described above, a sam-
ple being highly fragmented prior to library preparation does not definitively preclude it 
from sequencing; however, knowing fragment length informs downstream options (e.g., 
if material is highly fragmented, operators can opt to skip fragmentation steps within the 
library preparation). HPV positive (with known HPV sequence) and negative internal 
control samples are necessary to demonstrate that nucleic material has been correctly ex-
tracted during the extraction process. 
2.1.3. Specimen Enrichment Approach 
While HPV-positive clinical samples contain HPV nucleic acid, they are naturally 
dominated by nucleic acid from non-HPV sources (i.e., human and other-microbiome). If 
NGS is performed directly on the extract, without a targeted approach, the HPV content 
is at a relatively low proportion vs. the total nucleic acid sample. As the human genome 
length is 3 billion base pairs vs. ~8000 base pairs for HPV, the relative proportion of human 
nucleic acids extracted is +200,000%. 
Sequencing studies reveal that viruses typically represent less than 1% of the total 
genomic material detected in a human specimen [7], and therefore, detection of any virus 
by NGS formerly required subjecting specimens to either (a) host genome depletion or (b) 
viral enrichment, first. Different approaches to increase the viral component, include low-
speed or high-speed gradient centrifugation, separation of long chromosomal DNA, di-
gestion of nucleic acids not protected by virions (e.g., nuclease treatment), filtration to 
remove bacterial and host cells, or targeted sequence capture [31–36]. Each of these pro-
cedures may bias against detection of some viruses; therefore, pilot studies to validate 
accuracy and reproducibility of the method for the investigator’s specific purpose are nec-
essary. A variety of methods have been described to enhance the HPV content of a sample 
which are described below. 
(A). Depletion Protocols Using Saponin- or Lysis-Based Methods 
Saponin is a non-ionic surfactant that depletes the human genome affecting the path-
ogen-human DNA ratio [37,38]. MolYsis (Molzym, Germany) is a commercial product 
which works through selective lysis of host cells and associated degradation of released 
host DNA. Both products thus reduce the amount of host nucleic acid, enrichening the 
HPV DNA (or other desired bacterial, fungal, or viral DNA) while simultaneously 
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removing potential PCR inhibitors. However, replicating/intracellular viruses are also de-
pleted with these methods, and potential loss of viral signaling can occur, especially for 
viruses (such as HPV) that integrate in the human genome. 
A particular NGS application related to HPV is the detection of viral integration sites 
into the human genome. When performing WGS, authors have reported that tumors had 
either a small or a very large deletion in the viral genome and discovered that these dele-
tions were the result of either HPV integration into the human genome or HPV–HPV se-
quence junctions [39]. It has further been reported that at least 83% [40,41] of cervical can-
cers with HPV infection have HPV integration, which can occur at any chromosome but 
more frequently at certain fragile sites [42]. HPV integration can significantly increase re-
lated gene expression and has been associated with a worse survival rate (compared to 
those with episomal HPV) [43–46]. HPV integration status may therefore have promise as 
a biomarker for risk stratification [47–49], including the monitoring of treatment and ther-
apy. Different methods have been used to study HPV integration sites (e.g., amplification 
of HPV oncogene transcripts and detection of integrated HPV sequences by ligation-me-
diated PCR). With the development of NGS, whole-genome sequencing has been used for 
virus integration sites detection [50,51]. However, it requires large amounts of sequencing 
data, and thus is not applicable in clinical usage, which requires fast and accurate results. 
To date, the development of new NGS methods for HPV integration detection with high 
accuracy and prompt reporting capacity is ongoing [52]. However, the best way currently 
to detect integration sites is reached by using probe-captured sequencing methods (see 
section “Enrichment protocols” below). After enrichment of virus genomic material, the 
fusion fragment of human and HPV sequence is isolated and further sequenced by NGS. 
(B). Enrichment Protocols 
In addition to depletion protocols, the two most common enrichment protocols for 
HPV are PCR enrichment in the absence of chemical components and using capture pro-
tocols. PCR enrichment involves performing a PCR reaction prior to library preparation. 
For WGS, this technique may include amplification of the whole genome of the target 
virus via overlapping primers covering the entire genome (other techniques may not re-
quire amplification of the whole genome). A disadvantage of this technique is that there 
is a need to know the target that is to be sequenced a priori—thus, the method is not valid 
for detection of novel or nontargeted HPVs. Additionally, in the case of fragmented ma-
terial, the number of primers required can be high, which requires a structured a priori 
design approach, and the primers may vary in their affinity for the separate regions. Pri-
mer-dimer formation can also limit efficient target amplification, and therefore, pilot stud-
ies are needed to validate the protocol for each specific purpose [9,53]. 
To overcome these bottlenecks, unbiased amplification (not based on PCR) has been 
commonly used for viral enrichment, as it amplifies all DNA material present in the sam-
ple. Multiple displacement amplification (MDA) is the gold standard method for non-
PCR-based amplification techniques, where the reaction is based on annealing random 
hexamer primers to the DNA template [54]. MDA provides an effective way of amplifying 
minimal quantities of DNA, but there exist biases associated with this technology. Chi-
mera formation, preferential amplification of circular single stranded DNA, and nonuni-
form amplification of linear genomes have been documented [55,56]. Authors have quan-
tified the amount of amplification of both human DNA and HPV DNA by adding 20 cop-
ies/µL of HPV 16 plasmid to samples of human placental DNA at 1 ng/µL and reported 
an amplification of 26-fold for human DNA and 679-fold for HPV 16 DNA, suggesting 
that MDA is a good method for enriching circular HPV genomes [5]. Using MDA and 
NGS sequencing, researchers have been able to detect a plethora of novel HPVs as well as 
known HPV types, not detected by traditional PCR-based enrichment methods, among 
skin lesions/tumors and condyloma accuminata [3,4,7]. 
Another enrichment approach is to use a set of specific probes, “baits”, to recover 
HPV sequences from the entire genome of the virus. In brief, labelled biotinylated HPV 
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specific probes are captured by streptavidin coated magnetic beads after hybridization, 
resulting in “pure” HPV-derived reads. Consistent with the overlapping PCR approach, 
these probes need to be designed in advance but can be modified as required if low read 
numbers are obtained for some regions of the viral genome. Although it can be expensive, 
the advantage of the probes/baits approach is the large number of different probes one 
may include, allowing thousands of probes in one design. This means that it is possible to 
load the analysis with probes for all known HPVs, depending on purpose. Furthermore, 
it is the current gold standard method for integration studies [52]. 
Regardless of protocol applied, to validate the quality of host depletion or viral en-
richment, positive and negative control material must be added at the nucleic acid extrac-
tion step and carried through the enrichment/capture/depletion step and all stages of sub-
sequent analysis. As a positive control, cell line material infected with HPV is commonly 
used. However, we would recommend using specimens that contain both human DNA 
and HPV DNA in the typical concentrations that would correspond to real-life clinical 
specimens (99:1), as the sensitivity of the different approaches may vary. As a negative 
control, human DNA (HPV free, but containing the corresponding background “noise” as 
a true HPV-negative sample) or DNA-free water can be used. Note that if primer-based 
target enrichment is used, negative controls may contain noise such as primer-dimer 
bands when assessed by electrophoreses as well as unspecific amplification; these should 
be clearly discriminated from target sequences. Again, the introduction of homogeneous 
internal quality controls (IQCs) in the nucleic acid amplification should help in the iden-
tification of such issues. Internal positive control material demonstrates whether the de-
pletion/lysis has removed/reduced the HPV target in large proportion during the sample 
preparation stage. For the enrichment step, positive control material should reflect if am-
plification of the target regions/genome occurs and negative controls help determine 
whether any nonexpected amplification/targeting occurred. 
2.1.4. Direct Sequencing 
Several operators have opted for performing WGS directly after nucleic acid extrac-
tion, without enrichment. As described above, reaching a high sequencing depth is re-
quired, due to the low proportion of viral sequences typically present in the human spec-
imens. Direct sequencing has enabled an agnostic approach to DNA presence in clinical 
samples: while around 10% of cervical cancers are found to be negative for oncogenic 
HPVs by traditional PCR-based genotyping methods [57–61]; direct sequencing can reveal 
the presence of viral sequences of potentially causative HPVs in such cases [13,62]. Inter-
estingly, most of the HPVs detected with direct sequencing among the carcinomas nega-
tive by traditional PCR typing systems corresponded to HPV types within the explicit 
detection range of these assays. Therefore, the information obtained by direct sequencing 
can be used, not only to detect novel variants or types that may have escaped traditional 
amplification but also as a way to quantify and monitor shortfalls in detection due to sen-
sitivity issues. Furthermore, evidence suggests that HPV-negative cancer patients have a 
worse longitudinal prognosis [60,63,64]; this is reflected in the staging system for oropha-
ryngeal cancer which acknowledges the dichotomous disease status based on HPV pres-
ence [65] as does the recent WHO update for female genital tumors [66]. How “best” to 
annotate HPV status in cancer tissue is an area which arguably lacks consensus in the 
literature; however, NGS provides a powerful tool to at least resolve which cancer cases 
may be truly virally negative. 
2.1.5. Library Preparation and Sequencing 
At present, there are several different sequencing chemistries available. Each system 
has its own protocols and due to the diversity of platforms, and rapid pace of develop-
ments, we cannot recommend a specific one for all HPV applications. Akin to the assess-
ment and introduction of any new technology in-house, we strongly recommend valida-
tion that includes confirmation of expected results from “known” quality materials and 
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the evaluation of different kits with the specific analytical purpose in mind. For laborato-
ries looking to embed NGS into the accredited scope of their clinical service, initial vali-
dation followed by yearly verification would likely be mandatory. 
Quality, quantity, and fragment length analysis is a must to confirm success of library 
preparation. Library preparation protocols usually inform the operator about the concen-
tration and size expected for prepared libraries. If measurements do not reach the ex-
pected values, (e.g., fragments are too big/small or the library concentration is too diluted) 
optimization of fragmentation times, clean-up processes, or amplification steps should be 
performed. Larger fragments cluster less efficiently than smaller molecules, and a low 
concentration of prepared libraries translates into a low number of sequenced reads. Here, 
it is crucial to consider in which context libraries are analyzed; in a research study, subop-
timal measurements can occasionally be acceptable but probably never in a clinical con-
text where protocol adherence is paramount and actionable test results are needed. 
One also needs to perform accurate normalization to obtain homogeneous distribu-
tion (number of sequencing reads) of the samples and assure that the proper sequencing 
read length is used, depending on the insert size of the library. As an example, Illumina 
libraries prepared with dual-indexing that show a fragment length of 200 bp should not 
be sequenced with 2 × 150 bp, as part of the fragment length (around 130 bp) corresponds 
to adapter sequences, and the insert size, which is the actual query sequence, only com-
prises 70 bp (200 − 130 bp). Thus, 80 bp of the 150 bp sequenced (150 − 70 bp) does not 
contribute useful information. Libraries from positive and negative samples must be 
added into the final input dilution. Our recommendations for quality-control steps in the 
NGS workflow are summarized in Table 1. 
Table 1. Steps, potential quality issues, and proposed mitigations for next-generation sequencing (NGS) analytical work-
flow, with a focus on whole-genome sequencing purposes. 
Human Papillomavirus Detection by Next-Generation Sequencing 
NGS Step Possible Difficulties Mitigations 
Sample preparation 
Nucleic acid quality and/or quan-
tity outside library prep kit re-
quirements  
Selection of appropriate nucleic acid extraction methods.  
Pilot study comparing different extraction kits.  
Selection of enrichment or depletion protocol. 
Introduction of homogeneous internal quality controls 
Electrophoresis, bioanalyzer, and/or fluorometric quantita-
tion. Selection of further protocols based on the fragment size 
(e.g., use of shorter amplicons if DNA is highly fragmented) 
 Incorrect fragment size (too short 
or too long) 
Library preparation 
and sequencing 
Incorrect fragment size (too short 
or too long) 
Incorrect number of sequencing 
reads or partial reads 
Correct selection of library kit and fragment length. 
Correct selection of sequencing kit (e.g., 75 bp and 150 bp) to 
avoid sequencing adapters or longer fragments that insert 
size. 
Data analysis  Low sequencing depth  
Library preparation and sequencing piloting, and re-analysis 
Confirm reference sequence is correct. 
Use of updated database. 
In case of low sequencing depth at the beginning or end of the 
reference sequence, note that HPV is circular and not linear as 
the reference. 
Confirmation that desired alignment cut-offs are correct. 
  Incorrect alignment   
  
Mix/chimeras of microbial organ-
isms 
Filter reads—use of updated databases and careful settings of 
parameters. De novo assembly evaluation (HPV Chimera 
scripts) 
  Validation of pipeline 
Digital IQC, EQA, external assessment.  
Interlaboratory comparison 
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Storage Large amount of data 
Cloud services, compression of files, and storage of only raw 
input and final output. 
  Security 
Restricted super-user access, individually curated data access 
Analyst working only with coded/pseudonymized samples 
(where an independent database administrator holds the key 
code at another site) 
 Length of data storage Organization policy/data archiving laws and regulations 
2.2. NGS-Process Step 2: Bioinformatical Analysis 
2.2.1. Raw Sequence Data Management 
The output data from a sequencing machine are often referred to as raw data. Raw 
data management generally includes filtering steps to remove poor-quality data and host-
derived human reads and continues by mapping nonhuman high-quality reads directly 
to a known reference database or performing a de novo assembly approach,finishing with 
HPV taxonomy classification, phylogenetic analysis, and variant calling. There are several 
open-access tools that can be used to analyze “big data”. A set of bioinformatic algo-
rithms, when executed in a predefined sequence, is collectively referred to as a bioinfor-
matics “pipeline”. These pipelines can be designed in-house by teams with available 
bioinformatics expertise or obtained as ready-to-use applications from commercial sup-
pliers. The premade pipelines are principally aimed to users with little bioinformatic 
experience and act as a “blackbox” (user does not know which algorithm and calcula-
tion(s) are used by the pipeline). 
2.2.2. Sequence Analyses: Quality Assessment of Reads 
Each bioinformatical tool deployed in the pipeline uses different algorithms and pa-
rameters when handling data. When the objective of a project is to resolve a 0.5–1% dif-
ference between sequences, these differences in parameter settings could mean a different 
interpretation on nucleotide/mutation level is reached depending on which pipeline is 
being used. Ergo, two studies on the same nucleotide position could reach two different 
conclusions as to whether a mutation is present. 
Errors due to poor sample handling and storage conditions, polymerase bias, PCR- 
or qPCR-induced errors, and incorporation errors within sequencing may be introduced 
during sample preparation, amplification, library preparation, and sequencing stages. 
While these errors might not interfere with the identification of an HPV type (where the 
sequence divergence is 10% relative to its most closely related type), they might compro-
mise the identification of sublineages or variations in nucleotides that could have impli-
cations on accuracy, consistency, and, potentially, predicted phenotype. Careful sample 
handling, selection of a high-fidelity polymerase [67], and quality control of the raw data 
is a must [68]. 
Most analysis applications use FASTQ files as input for analysis; however, different 
sequencing instruments may give different extensions for raw sequencing data (e.g., Illu-
mina generates bcl files), and the first step is the conversion of those files to a standard 
format (FASTQ). Platforms usually provide software for the desired conversion (e.g., 
bcl2fastq from Illumina). Raw FASTQ files should be subjected to quality trimming and 
adaptor removal as a first step. Software for quality trimming and adaptor removal in-
clude Cutadapt, Trimmomatic, Trim Galore!, SeqTrim, and FastX among others [69]. 
Quality trimming is performed to remove low quality reads and aims to reduce the effect 
of the progressive decrease in sequencing quality with the increased length of the se-
quenced library. Trimming removes low quality portions of NGS reads while preserving 
the high-quality part of such a read. The user can specify the quality cut-off for a base or 
use a “sliding window” approach (defined as setting a cut-off for the average quality de-
tected in a number of X contiguous bases instead of just one base). Quality is usually 
checked according to the Phred quality scores, which are scores logarithmically related to 
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base-calling error probabilities [70]. As an example, a Phred quality score of Q30 corre-
sponds to a base calling accuracy of 99.9% (1 error per 1000 bp). The minimum quality 
recommended in the literature is a Phred quality score of 20 (99.0% accuracy; 1 error per 
100 bp), with the optimal quality however being above Q30 [71]. 
2.2.3. Alignment of Reads to a Suitable Human Reference Genome 
To obtain a dataset that contains only reads of interest, e.g., viral-related reads for 
HPV detection, nontarget sequences may be filtered out at the bioinformatics level to 
speed up downstream analysis and decrease the risk of misassemblies of genomic data. 
Most researchers applying WGS from sequenced extracted material opt for filtering out 
human genome sequences only (leaving HPV plus “other” microorganism reads). This is 
practical as human reads (according to our experience of multiple sequencing projects 
with a metagenomic perspective) account for approximately 90% of the total (with some 
variability depending on the sample origin) [7,13,62]. While several successive “versions” 
corresponding to human genome reference exist, it is recommended that the latest build 
(released in December of 2013), officially named GRCh38 (Genome Research Consortium 
human build 38) or commonly Hg38 (human genome build 38) is used. 
Numerous aligners exist so far and are being developed in order to achieve greater 
accuracy pertaining to precision. Widely used tools include BWA-MEM (Burrows-
Wheeler aligner) [72], SOAP2 [73], or Bowtie 2 [74], but several commercial tools are also 
available such as NextGenmap and Novoalign [75,76]. 
While some operators may, at this point, choose to filter out reads that are identical 
to the human reference genome (100% identical), another approach is to employ looser 
parameters which accept reads as human if the identity and coverage across the human 
genome sequence of interest are at least 95% and 75%, respectively. This latter approach 
allows for the detection of possible mutations not anticipated in the reference sequence, 
although this flexibility should be tempered so as not to misclassify nonhuman reads as 
human. An important thing to consider after performing the aligning/mapping to the hu-
man reference genome is to select which “unmapped” reads are to be used in downstream 
analysis. Sequencing with paired-end reads may contain (1) paired-end reads where both 
reads are unmapped, (2) paired-end reads where one of the pair read maps to the genome 
and the other does not. Operators may decide to discard nonhuman single reads and con-
tinue only with nonhuman paired-end reads, or to include them all; such a choice is en-
tirely dependent on coverage obtained and the aim of the project/resolution required. 
2.2.4. Alignment of Reads to a Suitable HPV Reference Database 
Once human (or host) sequences are filtered out from the high-quality data set, most 
operators align reads to a known and curated HPV database for HPV classification or to 
the reference HPV genome in question. Currently, there are 222 different HPV types offi-
cially established (data accessed on 18 March 2021 from Hpvcenter.se) and another 220 
putative novel HPV types (not cloned and investigated by the International HPV Refer-
ence Center) whose complete sequence can be found in the public database from the pap-
illomavirus Episteme (data accessed on 18 March 2021 at https://pave.niaid.nih.gov/). 
Furthermore, there are many partial genomic sequences of HPV isolates (not all spec-
ifying which HPV type they correspond to) available at public databases, with GenBank 
having >33,500 hits retrieved when typing “human papillomavirus” (data accessed on 18 
March 2021). A recent publication [77] detected up to 0.5% chimeric sequences and/or tax-
onomy errors when analyzing HPV sequences in the GenBank database. This highlights 
the importance that the database be obtained from a quality reference repository and that 
local curation is performed before doing any type of alignment, such as checking for po-
tential errors and updates. In-house databases belonging to individual investigators 
should be periodically updated with canonical or reference types, as new HPV types are 
continuously being discovered [5,78]. 
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It is particularly key to note that, when aligning the sequencing reads to a specific 
HPV genotype, operators ascertain that the correct reference sequence is used. There are 
3650 sequences belonging to HPV16 isolates in GenBank (sequence length 7500–8500, data 
accessed on 18 March 2021), showing differences that may reach up to 10% of the total 
genome. If each separate investigation were to use a different sequence as reference ge-
nome, then comparison between publications becomes challenging at best. The reference 
genomes that should be used for each HPV type are provided at the International HPV 
Reference Laboratory website (Hpvcenter.se); accessed 7 July 2021, as well as at the pap-
illomavirus Episteme database (https://pave.niaid.nih.gov/; accessed 7 July 2021). The lat-
ter resource has a contemporary collection of internationally ratified sequences from the 
reference clones corrected for known sequencing mistakes in the original sequences. 
2.2.5. Identification of HPV Types/Lineage/Sublineages 
Classification of HPVs is based on the nucleotide sequence homology of the L1 gene, 
which is the most conserved region of the viral genome. Within the family, different gen-
era share less than 60% nucleotide similarity. Within each genus, different species share 
between 60% and 70% similarity. Below the species level, a novel HPV type shares less 
than 90% similarity to any other type [79–81]. The definition of a variant lineage is that the 
L1 open-reading frame differs by more than 1%, but less than the 10% that would make it 
another HPV type [82]. A variant sublineage is defined as groups of sequences with 0.5–
1.0% differences between genomes [83]. 
There exist different tools for the identification of variants. One of the most used and 
user friendly is BLAST [84]. This tool compares the sequence under investiagation to se-
quences stored in the database, detailing statistical significance of matches. Again, the im-
portance of using standard references for HPV variants is essential. Burk et al. described 
the representative genomes for viral variant lineages and sublineages, and most authors 
rely on these sequences as variant lineages references [82]. 
If a phylogenetic analysis is required, different open-source tools exist (RaxML, 
MegaX) that infer phylogenetic trees after choosing the statistical method [85,86]. 
2.2.6. Evaluation of Coverage across the Genome 
If the purpose is to detect HPV genotypes (not within-genotype specific variant call-
ing), once the reads are aligned to the HPV database, we recommended that cut-offs are 
applied on which HPV positivity is based (Table 1). 
This could be, e.g., setting a minimum of 10 reads detected for a specific HPV type 
together with a coverage of at least 10% of the HPV genome (around 800 bp coverage). 
This approach would avoid false positivity generated by background noise (e.g., presence 
of many low complexity reads mapping to just a small region of the genome). If phyloge-
netic analysis or variant calling is required, a FASTA file with the “query” sequence must 
be created. When creating a FASTA file from the obtained sequencing reads/contigs, in-
vestigators should be aware of the extent of genome coverage to see if there are missing 
regions 
Evaluating the full coverage of the sequence is important, as several tools that convert 
the sequencing reads into a FASTA file use a reference sequence to account for the regions 
that are not covered. The use of “N”s is recommended for the positions that are not cov-
ered by the sequencing reads. For variant lineage assignment, exclusion must be consid-
ered for specimens with poor read depth (<200 median depth) and/or low genome cover-
age (<80% genome coverage)[53]. For variant calling, even stricter cutoffs should be ap-
plied. Additionally, further steps including marking duplicates to identify read pairs 
likely to have originated from duplicates of the same original DNA fragments and recali-
bration of base quality scores should be performed, as suggested by the best practices at 
GATK[87]. Considering just the base depth as a cutoff for variant calling (e.g., five reads 
per position) is not enough to assure accurate calling. It is essential to differentiate be-
tween true positive variants and false positive variants. Parameters and statistics which 
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describe how many reads cover the variant, what proportion of reads are in forward vs. 
reverse orientation, and what the sequence context is like around the variant site should 
be considered. 
2.2.7. De Novo Assembly of HPV Contigs 
When the correct reference genome is not known, the (re-)construction of the se-
quenced genome must be performed without a priori knowledge of either the correct orig-
inal sequence (or the order of the DNA fragments), by assembling overlapping reads into 
one or more contigs. This process is known as de novo assembly. Subsequent post assem-
bly assessment is mandatory to reduce the risk of chimeric sequences and possible mis-
calling of HPV positivity in samples and/or erroneous calling of new HPV variants/geno-
types. HPV-Chimera scripts exist to help researchers determine the accuracy of their HPV 
contigs [12,77]. 
2.2.8. Digital Quality Assessment 
While positive and negative controls can be incorporated into laboratory experiments 
and several quality check-points are available during the whole laboratory process, we 
currently lack an agreed approach for the quality control of bioinformatical tools and pipe-
lines. Digital IQCS can be prepared from confirmed and verified positive material and 
stored as FASTQ files (raw data). Interlaboratory exchange of data can provide reassur-
ance by comparing results on sequences derived from the same specimens. However, this 
requires resources and collaboration which may not always be available in the short term. 
Therefore, it would be beneficial to have positive IQCS available in an online repository 
that could be used to verify the pipeline when setting up a new service/test or when a tool 
is updated. 
2.2.9. Journal Submission Requirements 
Recently, several journals have started to request that all authors who submit manu-
scripts containing NGS data provide a detailed summary of sequencing coverage and 
quality statistics. For example, the International Journal of Cancer requires a summary 
from submitting authors that must include all information about library preparation, se-
quencing technology information (e.g., platform, read length, and paired-end/single read 
approach), as well as preprocessing, quality control, and filtering of the raw NGS data 
[88]. Furthermore, the sequencing coverage and quality statistics of each sample must be 
summarized as a Supplementary Table. 
2.2.10. HPV NGS in Clinical Settings 
Application of NGS for clinical testing requires a level of quality assurance and mon-
itoring likely to be even more stringent than systems set up in research laboratories. Ver-
ification and validation for each of the steps that make up the NGS process is the key to 
obtain and provide reliable results to clinicians and patients. Any minor change of the 
wet-lab protocol or any parameter in the data analysis requires a full verification with 
previously known samples/sequences. This in combination with the external quality as-
sessment, and accreditation helps ensure the validity of the clinical results. 
2.2.11. External Quality Assessment and Accreditation 
Suppliers of EQA schemes have developed external quality materials to support NGS 
sequencing results for various pathogens and human genes (e.g., GenQA, Statens Serum 
Institut, and QCMD (pilot)). At time of publication, we are not aware of any official HPV 
EQA scheme to support NGS for wet and in silico analysis or indeed data/dry analysis. 
This is arguably a current deficit, as while interlaboratory exchange of materials is un-
doubtedly helpful for quality assurance and validation of HPV NGS, such exchanges do 
not wholly “stand in” for consistent performance in a formal accredited EQA scheme(s). 
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Should HPV NGS move to the diagnostic context, then this would increasingly require 
address. 
2.2.12. Data Storage Requirements 
Data storage demands of NGS are often very large and need to be carefully consid-
ered before local implementation. Unfortunately, there is no (international) consensus on 
what and how data should be stored beyond the general recommendation that it should 
be stored in line with national and local capacity and governance policies. In high-level 
terms, we recommend storing the raw FASTQ files in a compressed mode (.fastq.gz), the 
final output, and the full-log file (documentation on the software/tools used, including 
versions, parameters, and github location, needed to obtain the output files) making the 
whole analysis reproducible. 
If intermediate files are to be kept, they should be stored as standard open-file for-
mats FASTQ, BAM, and VCF, facilitating the exchange with other laboratories, where 
governance permits. Cloud-based storage could be a very helpful tool; however, this may 
be challenging to reconcile with data protection. Currently, most journals ask for data 
availability and request that authors upload all nonhuman sequences detected in the 
study to different databases (such as the European Nucleotide Archive (ENA), Sequenc-
ing Read Archive (SRA), and Genbank) to make research publicly available and re-usable 
for other scientists without compromising confidentiality. 
3. Discussion 
Next-generation sequencing (NGS) has enabled researchers to detect human papillo-
mavirus (HPV) infections with unprecedented sensitivity and accuracy while simultane-
ously providing the whole viral sequence to be analyzed for viral point mutations, variant 
lineages, and genome variations. Increasing incorporation of NGS into laboratories for 
research, epidemiology, and diagnostic purposes may be only a matter of time, particu-
larly as costs reduce with increasing demand and competition. 
Certainly, the use of NGS for clinical workstreams generally requires accredita-
tion/auditing from an independent regulator. As an example, the National Accreditation 
Body for the United Kingdom (UKAS) now has expertise to assess and accredit labs that 
have NGS in scope, working to ISO 15189:2012 standards. This process covers assessment 
of staff training, quality control of pipelines, initial validation of the whole process com-
pared to a gold-standard approach, and reproducibility of results plus checks to ensure 
security of data and access is correct. The magnitude of the effort to achieve accreditation 
in a particular service laboratory is likely to depend on local support for the integration of 
NGS to support public health epidemiology and precision medicine in general terms. The 
SARS-CoV-2 pandemic has brought about an exponential increase in molecular testing 
and associated infrastructure, including that required to support sequence-level variant 
detection. This is likely to pay dividends for the establishment of “cross organism work-
ing” to a diagnostic standard [89]. Certainly, NGS has the potential to support risk strati-
fication of patients with HPV-associated disease through its ability to detect types within 
tissue with exquisite sensitivity and through providing subtle insights into aspects of HPV 
infection that may be predictive of outcome (integration pattern and status, delineation of 
dominant variant(s), and viral load). NGS may also be applied to liquid biopsies, from 
blood, to support longitudinal monitoring of treatment success [90]. 
The bulk of HPV sequencing to date has been performed using the IonTorrent ini-
tially [9,11,91], followed by the newer Illumina platform [7,53,57]; some very recent stud-
ies have also used nanopore platforms [52,92]. While many studies report higher sensitiv-
ity and accuracy when comparing NGS to routine genotyping methods [6,8], there are 
very few studies where one HPV NGS approach has been directly compared to another 
in a head-to-head approach using the same sample set [93,94]. Hence, there are fewer data 
available compared to the relative wealth of peer-reviewed literature on head-to-head 
performance of traditional HPV molecular assays. While many researchers are already 
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using NGS for detection and analysis of HPV-associated diseases, there is no clear inter-
national consensus about what steps are to be performed nor which quality criteria are 
appropriate. 
Typically, published presequencing laboratory protocols appear well validated for 
providing detail on clear-quality assessment procedures and specifying the requirements 
needed for library preparation evaluation and success. Nevertheless, even though the in-
clusion of positive and negative controls should be a must, the presence and/or descrip-
tion of these controls is not commonly found within NGS publications. This may be in 
part due to the relatively high cost of NGS. Hornung et al. reviewed ~265 publications 
which had used NGS for microbiome research and found that only 30% of publications 
used any type of negative controls and that less than 10% reported positive controls. Ad-
ditionally, they observed that some of the results reported were potentially indistinguish-
able from contaminants [95]. 
Furthermore, to the best of our knowledge, quality assessment of bioinformatic anal-
ysis appears not to be as standardized, when compared to the analytical sample handling 
stages. However, we consider it key that the use of a curated and updated databases, use 
of standard reference genome sequences, and description of the parameters used for each 
step should be described fully in all publications. 
The present piece aims to describe and summarize the application of WGS for HPV 
detection and has mainly focused on DNA detection to detect the whole HPV sequence. 
Nevertheless, RNA sequencing should not be forgotten as an alternative method for HPV 
detection, as RNA transcription not only enables detection of HPVs but provides further 
information on the active HPV infection that drives viral oncogene expression. In the can-
cers that are known to be caused by HPV, transcription of viral genes is necessary for viral 
pathogenicity [96]. Studying transcription of the E6 and E7 oncogenes has been useful to 
elucidate which infections are likely to be involved in the etiology of the tumor, e.g., in 
head and neck cancer studies [97–99]. Even though RNA sequencing is not usually per-
formed within studies aiming to analyze the whole HPV genome (as noncoding regions, 
e.g., URR, are not detected if RNA extraction and sequencing are performed), important 
information about active infection and viral oncogene expression is obtained with this 
sapproach. 
International collaboration is essential to efficiently further knowledge, scientific de-
velopment, and concerted efforts to combat globally prevalent viral infections. In the case 
of HPV, the International HPV Laboratory Network LabNet was created by WHO in 2006 
to support global development of laboratory standardization and quality assurance of 
HPV detection methods. LabNet concentrated on evaluating and improving methods 
used for research and evaluation of HPV-based screening and vaccination [100]. As part 
of this effort, LabNet published an HPV laboratory manual, based on knowledge and ex-
perience gained through international collaborative studies, aiming to assist in establish-
ing the laboratory support required for HPV research [101]. The successor to LabNet, the 
International HPV Reference Center (Hpvcenter.se), aims to support reliable and compa-
rable HPV detection services, allowing data to be internationally comparable. The Center 
has organized and issued global proficiency panels (sets of blinded samples containing 
HPV genotypes at different concentrations) since 2008, and a definite improvement in av-
erage assay performance globally has been seen since the panel was issued [102]. The 
SHPVRL has also acted as a hub laboratory to support the creation of materials and best 
practice documents to facilitate the introduction of new HPV technologies and their con-
tinued monitoring [103,104]. 
Together. we now work between our two laboratories to exchange samples, know-
how, and protocols for bioinformatical flow and sequence analyses. Hopefully, this will 
strengthen the quality of work produced by both settings and act as a catalyst/model for 
future international endeavors. We propose that it is time for NGS to be included in the 
global efforts on quality assurance and improvement in HPV-based testing and diagnos-
tics. By establishing a set of quality standards and best-practice statements, the 
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community could systematically develop and apply NGS guidelines suited for HPV re-
search, epidemiology, and diagnostics to ensure this innovative and powerful technology 
is developed in an internationally comparable and robust manner. 
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